Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine in frontline Higher-Risk Myelodysplastic Syndromes and frontline TP53 mutant...

Related Keywords

Texas ,United States ,Boston ,Massachusetts ,North Carolina ,American ,Taylor Schreiber ,Conor Richardson ,Mirvetuximab Soravtansine ,Cancer Research ,Rna Work In Cancer Research ,Shattuck Labs Inc ,Ono Pharmaceutical Co Ltd ,Exchange Commission ,Development Rd Expenses ,Nasdaq ,Health Care Conference Boston ,American Society Of Hematology ,Higher Risk Myelodysplastic Syndromes ,Acute Myeloid Leukemia ,American Society ,Annual Meeting ,Chief Executive Officer ,Cancer Cell ,Milestones Expected ,Stage Pipeline ,Initial Enrollment ,Ongoing Phase ,Clinical Trial ,Presented Positive Interim Data ,Acquired Resistance ,Annual Health Care Conference ,Global Biopharma Conference ,Biotechc Suite Fireside Chat Series ,Cancer Research Annual Meeting ,San Diego ,Ono Enter ,Collaboration Agreement ,Closes Financing ,Cash Equivalents ,Shattuck Labs ,Agonist Redirected Checkpoint ,Annual Report ,Safe Harbor ,Private Securities Litigation Reform Act ,Media Contact ,Ended December ,Diluted Per Common Share Data ,